Skip to main content
SpringerLink
Log in

An examination of the radioprotective and radiorecovery activities of Fe(III)(3,5-diisopropylsalicylate)3 and Mn(III)2(II)(μ3-O))(3,5-diisopropylsalicylate)6

  • Published:
InflammoPharmacology Aims and scope Submit manuscript

Abstract

Manganese(III)2(II)(μ3-O))(3,5-diisopropylsalicylate)6 [Mn3(O)(3,5-DIPS)6] and iron(III)(3,5-diisopropylsalicylate)3 [Fe(3,5-DIPS)3] were used to treat LD100/30 irradiated mice before or after irradiation to compare their efficacy in the prevention or recovery from radiation-induced systemic inflammatory disease, loss of body mass, and in increasing survival. Two hundred C57BL/6 mice were divided into eight groups of twenty-five mice with four groups given doses of 0, 40, 80, or 160 μmol/kg body mass of Mn3(O)(3,5-DIPS)6 by oral administration prior to irradiation, and four groups given doses of 0, 20, 40, or 80 μmol/kg body mass post-irradiation. A dose of 0, 20, 40, or 80 Fe(3,5-DIPS)3 μmol/kg was administered subcutaneously prior to irradiation or 0, 10, 20, or 40 μmol/kg after irradiation. Treatment with either Mn3(O)(3,5-DIPS)6 or Fe(3,5-DIPS)3 failed to prevent the radiation-induced decrease in body mass however both the Mn and Fe complex-treated groups generally appeared to lose less body mass and recovered with a higher rate of increase in body mass than the vehicle-treated control groups. Treatment with 20 μmol/kg Fe(3,5-DIPS)3 prior to irradiation produced a 200% increase in survival compared to the vehicle-treated control group while treatment with doses of 40 μmol/kg or 80 μmol/kg Fe(3,5-DIPS)3 did not increase survival. No dose of Fe(3,5-DIPS)3 given after irradiation increased survival. Mn3(O)(3,5-DIPS)6-treated mice fared better. However, statistically significant (p≤0.05) improvement in survival was only found for the group given 160 μmol/kg Mn3(O)(3,5-DIPS)6 orally prior to irradiation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sorenson JRJ. Essential metalloelement metabolism and radiation protection and recovery. Radiat Res. 1992;132:19–29.

    Article  PubMed  CAS  Google Scholar 

  2. Sorenson JRJ, Soderberg LSF, Chang LW et al. Copper-, iron-, manganese-, and zinc-3,5-diisopropylsalicylate complexes increase survival of gamma-irradiated mice. Eur J Med Chem. 1993;28:221–9.

    Article  CAS  Google Scholar 

  3. Henderson TD, Burt RL, Kaufman SE, Willingham WM, Sorenson JRJ. Radiorecovery activity of manganese(III)2(II)(μ3-O))(3,5-diisopropylsalicylate)6. Radiat Res. 1993;136:126–9.

    Article  PubMed  CAS  Google Scholar 

  4. Henderson TD, Henderson RD, Irving HJ, Willingham WM, Sorenson JRJ. Radiorecovery and prophylactic-treatment efficacies of manganese(III)2(II)(μ3-O))(3,5-diisopropylsalicylate)6 in gamma irradiated mice. Inflammopharmacology. 1995;3:241–50.

    Article  CAS  Google Scholar 

  5. Sorenson JRJ, Melby EG, Nord PJ, Petering HG. Interference in determination of metallic elements in human hair. An evaluation of zinc, copper, lead and cadmium, using atomic absorption spectrophotometry. Arch Envir Health. 1973;27:36–9.

    CAS  Google Scholar 

  6. Soderberg LSF, Barnett JB, Baker ML, Salari H, Sorenson JRJ. Copper(II)(3,5-diisopropylsalicylate)2 accelerates recovery of B and T cell reactivity following irradiation. Scand J Immunol. 1987;26:495–502.

    Article  PubMed  CAS  Google Scholar 

  7. Soderberg LSF, Barnett JB, Baker ML, Salari H, Sorenson JRJ. Copper(II)2(3,5-diisopropylsalicylate)4 stimulates hemopoiesis in normal and irradiated mice. Exp Haematol. 1988;16:577–80.

    CAS  Google Scholar 

  8. Soderberg LSF, Barnett JB, Baker ML, Salari H, Sorenson JRJ. Post-irradiation treatment with copper(II)2(3,5-diisopropylsalicylate)4 enhances recovery and hematopoietic regeneration. Exp Haematol. 1990;18:801–5.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biopharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, 72205, Little Rock, Arkansas

    H. J. Irving, M. A. Wear, L. G. Tipton, J. B. Tipton, K. M. Maddox & J. R. J. Sorenson

  2. Department of Chemistry, University of Arkansas at Pine Bluff, 71601, Pine Bluff, Arkansas, USA

    H. Simmons & W. M. Willingham

Authors
  1. H. J. Irving
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. A. Wear
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Simmons
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. G. Tipton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. B. Tipton
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. M. Maddox
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W. M. Willingham
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. R. J. Sorenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Irving, H.J., Wear, M.A., Simmons, H. et al. An examination of the radioprotective and radiorecovery activities of Fe(III)(3,5-diisopropylsalicylate)3 and Mn(III)2(II)(μ3-O))(3,5-diisopropylsalicylate)6 . Inflammopharmacology 4, 309–321 (1996). https://doi.org/10.1007/BF02755784

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02755784

Keywords

Search

Navigation